Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer : Episode 4
Opinion
Video
Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC
The panel examines how resistance mutations influence the effectiveness of subsequent treatment lines and delves into the process of selecting later-line therapies based on follow-up next-generation sequencing results.
EP: 1.Biomarker Testing Best Practices in HR+/HER2- mBC
EP: 2.First-Line Treatment Options in HR+/HER2- and Challenges with Treatment Resistance
EP: 3.Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
Now Viewing
EP: 4.Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC
- How does the identification of resistance mechanisms impact your clinical decision making? Do resistance mutations impact efficacy of later-line treatments?
- How does treatment resistance after 1L treatment create challenges in selecting 2L therapies?
- How do you weigh efficacy, toxicity, and patient quality of life when selecting 2L treatment?
- On the other hand, how might the identification of actionable mutations allow for optimalselection of targeted treatment options in later-lines?
- How are targeted therapies directed at actionable mutations changing the treatment paradigm?
Related Videos
Related Content
